Fagron NV (FAGR) - Total Liabilities
Based on the latest financial reports, Fagron NV (FAGR) has total liabilities worth €925.69 Million EUR (≈ $1.08 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Fagron NV long-term investment allocation to see how much of total assets are deployed in long-term investments.
Fagron NV - Total Liabilities Trend (2004–2025)
This chart illustrates how Fagron NV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Fagron NV's balance sheet.
Fagron NV Competitors by Total Liabilities
The table below lists competitors of Fagron NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PSMC CO. Ltd
KQ:024850
|
Korea | ₩46.05 Billion |
|
Airport City Ltd
TA:ARPT
|
Israel | ILA8.99 Billion |
|
Hangzhou Shunwang Tech
SHE:300113
|
China | CN¥397.87 Million |
|
Allient Inc.
NASDAQ:ALNT
|
USA | $281.63 Million |
|
Guangdong Guangzhou Daily Media Co Ltd
SHE:002181
|
China | CN¥824.39 Million |
|
Ningbo PIA Automation Holding Corp. A
SHG:688306
|
China | CN¥2.93 Billion |
|
Shinkong Insurance Co Ltd
TW:2850
|
Taiwan | NT$40.58 Billion |
|
Shenzhen Bluetrum Technology Co. Ltd. A
SHG:688332
|
China | CN¥630.58 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Fagron NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See FAGR equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fagron NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fagron NV (2004–2025)
The table below shows the annual total liabilities of Fagron NV from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €686.87 Million ≈ $803.03 Million |
+18.80% |
| 2024-12-31 | €578.16 Million ≈ $675.93 Million |
+7.20% |
| 2023-12-31 | €539.33 Million ≈ $630.53 Million |
-4.10% |
| 2022-12-31 | €562.38 Million ≈ $657.48 Million |
+18.41% |
| 2021-12-31 | €474.95 Million ≈ $555.27 Million |
-4.05% |
| 2020-12-31 | €495.01 Million ≈ $578.72 Million |
-10.78% |
| 2019-12-31 | €554.80 Million ≈ $648.62 Million |
+17.28% |
| 2018-12-31 | €473.06 Million ≈ $553.05 Million |
+15.61% |
| 2017-12-31 | €409.17 Million ≈ $478.36 Million |
-42.79% |
| 2016-12-31 | €715.18 Million ≈ $836.12 Million |
-5.17% |
| 2015-12-31 | €754.15 Million ≈ $881.69 Million |
-7.67% |
| 2014-12-31 | €816.81 Million ≈ $954.94 Million |
+25.75% |
| 2013-12-31 | €649.53 Million ≈ $759.36 Million |
+29.00% |
| 2012-12-31 | €503.51 Million ≈ $588.66 Million |
+9.51% |
| 2011-12-31 | €459.78 Million ≈ $537.53 Million |
+25.81% |
| 2010-12-31 | €365.47 Million ≈ $427.27 Million |
+32.51% |
| 2009-12-31 | €275.81 Million ≈ $322.45 Million |
+18.78% |
| 2008-12-31 | €232.20 Million ≈ $271.47 Million |
+37.20% |
| 2007-12-31 | €169.24 Million ≈ $197.86 Million |
-11.19% |
| 2006-12-31 | €190.58 Million ≈ $222.80 Million |
+0.74% |
| 2005-12-31 | €189.17 Million ≈ $221.16 Million |
+10.85% |
| 2004-12-31 | €170.65 Million ≈ $199.51 Million |
-- |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more